In this study, we focused on the utility of TNF-α -308G/A polymorphisms, NLR, and PLR as potential biomarkers in AS, RA, and PsA, as well as the role of TNF-α -308G/A polymorphisms in combination with NLR and PLR in predicting the efficacy and safety of anti-TNF-α therapy. This evidence concerns the gene TNF and rheumatoid arthritis.